- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus (T2DM)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Dulaglutide – November 2019
Dulaglutide: Injection 1.5 mg in 0.5 mL single dose pre-filled pen; Trulicity®
Last updated
20 March 2020